Novus Therapeutics, Inc. Announced It Has Completed The Acquisition Of Anelixis Therapeutics, Inc. (&Ldquo;Anelixis&Rdquo;), A Privately Held Clinical Stage Biotechnology Company Developing A Next Generation Anti-Cd40 Ligand (Cd40L) Antibody As A Potential Treatment For Organ And Cellular Transplantation, Autoimmune Diseases, And Neurodegenerative Diseases. Concurrent With The Acquisition Of Anelixis, Novus Entered Into A Definitive Agreement For The Sale Of Non-Voting Convertible Preferred Stock (The &Ldquo;Preferred Stock&Rdquo;) In A Private Placement To A Group Of Institutional Accredited Investors Led By Bvf Partners L.P., With Participation From Cormorant Asset Management, Ecor1 Capital, Logos Capital, Fidelity Management And Research Company, Adage Capital Partners L.P., Woodline Partners Lp, Ridgeback Capital, Janus Henderson Investors, And Samsara Biocapital, As Well As Additional Investors. The Private Placement Is Expected To Result In Gross Proceeds To Novus Of Approximately $108 Million Before Deducting Placement Agent And Other Offering Expenses. The Proceeds From The Private Placement Will Be Used To Fund The Company&Rsquo;S Operations, Including To Advance Phase 2 Clinical Trials Of At-1501, A Humanized Igg1 Anti-Cd40L Antibody With High Affinity For Cd40L, In Renal Transplantation, Islet Cell Transplantation, Autoimmune Nephritis, And Amyotrophic Lateral Sclerosis (Als).&Ldquo;We Are Excited About At-1501 And The Potential To Develop And Commercialize The Next Generation Anti-Cd40L Antibody, A Well-Validated Target With Broad Therapeutic Possibilities,&Rdquo; Said Keith A. Katkin, Chairman Of The Board Of Directors Of Novus. &Ldquo;After Exploring A Range Of Strategic Options To Maximize Shareholder Value, We Believe This Acquisition Represents The Greatest Value Creation Opportunity For Novus Stockholders, And We Are Confident That We Have The Management And Scientific Leadership Team To Fully Realize This Opportunity For Patients In Need Of New Treatment Options
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!